Physiotenses - instructions for use, analogs, reviews and release forms (tablets 0.2 mg, 0.3 mg and 0.4 mg) drugs for the treatment of hypertension and pressure reduction in adults, children and pregnancy

In this article, you can read the instructions for using the drug Physiotherapy. There are reviews of visitors to the site - consumers of this medication, as well as opinions of physicians specialists on the use of Physiotense in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Physiotense in the presence of existing structural analogues. Use to treat hypertension and reduce blood pressure in adults, children, as well as during pregnancy and lactation.

Physiotherapy - an antihypertensive drug of central action.

Moxonidine (the active substance of the Physiotense drug) is an antihypertensive drug with a central mechanism of action. In stem brain structures (the rostral layer of the lateral ventricles), Moxonidine selectively stimulates imidazoline-sensitive receptors that participate in tonic and reflex regulation of the sympathetic nervous system. Stimulation of imidazoline receptors decreases peripheral sympathetic activity and blood pressure.

Physiognosis differs from other sympatholytic antihypertensive agents with a lower affinity for alpha2-adrenergic receptors, which explains the lower probability of developing sedation and dry mouth.

The administration of moxonidine leads to a decrease in systemic vascular resistance and blood pressure. The hypotensive effect of moxonidine is confirmed in double-blind, placebo-controlled, randomized studies.

Physiotensis improves by 21% the index of insulin sensitivity (compared to placebo) in patients with obesity, insulin resistance and moderate degree of hypertension.

Composition

Moxonidine + excipients.

Pharmacokinetics

After oral administration, Physiotens is quickly and almost completely absorbed in the upper GI tract. Eating does not affect the pharmacokinetics of the drug. The main metabolite of moxonidine is dehydrogenated moxonidine and guanidine derivatives. The pharmacodynamic activity of deoxidized moxonidine is about 10% compared to moxonidine. Within 24 hours, more than 90% of moxonidine is excreted by the kidneys (about 78% unchanged and 13% in the form of dehydrogenomycosidine, while other metabolites in the urine do not exceed 8% of the dose taken). Less than 1% of the dose is excreted through the intestine.

Pharmacokinetics in special clinical cases

In comparison with healthy volunteers, patients with hypertension do not have any changes in the pharmacokinetics of moxonidine.

Clinically insignificant changes in pharmacokinetic parameters of moxonidine in elderly patients, probably caused by a decrease in the intensity of its metabolism and / or slightly higher bioavailability, were noted.

Moxonidine is not recommended for use in patients under the age of 18 years, and therefore no pharmacokinetic studies have been performed in this group.

Indications

• arterial hypertension.

Forms of release

Tablets coated with 0.2 mg, 0.3 mg and 0.4 mg.

Instructions for use and dosing regimen

Tablets are taken orally, regardless of food intake.

In most cases, the initial dose of Physiotense is 200 μg per day. The maximum single dose is 400 μg. The maximum daily dose, which should be divided into 2 divided doses, is 600 mcg.

Individual correction of the daily dose is necessary depending on the patient's tolerability of the therapy.

Dose adjustment for patients with hepatic insufficiency is not required.

The initial dose for patients with moderate or severe renal failure, as well as those on hemodialysis is 200 μg per day. If necessary and with good tolerability, the daily dose can be increased to a maximum of 400 μg.

Side effect

• dry mouth;
• dizziness;
• asthenia and drowsiness;
• headache;
• dizziness (vertigo);
• drowsiness;
• fainting;
• marked decrease in blood pressure;
• orthostatic hypotension;
• bradycardia;
• diarrhea;
• nausea, vomiting;
• dyspepsia;
• skin rash;
• itching;
• angioedema;
• nervousness;
• tinnitus;
• backache;
• pain in the neck;
• peripheral edema.

Contraindications

• syndrome of weakness of the sinus node;
• pronounced bradycardia (heart rate at rest less than 50 bpm);
• AV blockade of 2 or 3 degrees;
• acute and chronic heart failure;
• lactation period;
• age under 18 years (due to lack of safety and efficacy data);
• hereditary intolerance to galactose, lactase deficiency or malabsorption of glucose / galactose;
• hypersensitivity to the active substance and other components of the drug.

Application in pregnancy and lactation

Pregnancy

Clinical data on the use of Physiotense in pregnant women are absent.

In the course of animal studies, the embryotoxic effect of the drug was established.

Physiotensis should be given to pregnant women only after a thorough assessment of the risk-benefit relationship, when the benefit to the mother exceeds the potential risk to the fetus.

Lactation period

Moxonidine penetrates into breast milk and therefore should not be administered during lactation. If you need to apply Physiotense in the lactation period, breastfeeding should be discontinued.

special instructions

At present, there is no evidence that stopping the use of the Physiotense drug leads to an increase in blood pressure. However, it is not recommended to stop taking the Physiotense drug abruptly, instead you should gradually reduce the dose of the drug within two weeks.

Influence on the ability to drive vehicles and manage machines and mechanisms

Studies of the effect of the drug on the ability to drive and other mechanisms have not been carried out. There are reports of drowsiness and dizziness during treatment with moxonidine, which should be taken into account in patients who engage in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Drug Interactions

The combined use of moxonidine with other antihypertensive agents leads to an additive effect.

Tricyclic antidepressants can reduce the effectiveness of antihypertensive agents of central action, and therefore it is not recommended that they be taken together with moxonidine.

Physiotension can enhance the effect of tricyclic antidepressants, tranquilizers, ethanol (alcohol), sedatives and hypnotics.

Moxonidine is able to moderately improve impaired cognitive function in patients receiving lorazepam.

Moxonidine may enhance the sedative effect of benzodiazepine derivatives when administered concomitantly.

Moxonidine is excreted by tubular secretion. Therefore, its interaction with other drugs released by tubular secretion is not excluded.

Analogues of the Physiotense drug

Structural analogs for the active substance:

• Moksogamma;
• Moxonidine;
• Moxonitex;
• Stencil;
• Tsint.

Similar medicines:

Other medicines: